| Releases |
 |
Biodel to Present at the Wedbush Life Sciences Conference
Jul 29, 2010
|
8.6 KB |
|
| |
DANBURY, Conn., July 29, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the Company will present at the Wedbush Securities Life Sciences Best Ideas Management Access Conference on Tuesday, August 3rd. Dr. Errol De Souza, President and Chief Executive Officer will make a presentation on the company at 1...
|
|
Biodel Reports Progress with Development of Glucose-Regulated 'Smart' Basal Insulin
Jul 12, 2010
|
12.9 KB |
|
| |
DANBURY, Conn., July 12, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) today reported results of preclinical tests which demonstrated the potential of the company's glucose-regulated or "smart" basal insulin product candidate, BIOD620, to release insulin proportionally in response to changing glucose conditions. In an ora...
|
|
Biodel Announces Research Grants by Juvenile Diabetes Research Foundation to Evaluate Use of VIAject(R) in Treatment of Diabetes
Jul 12, 2010
|
12.1 KB |
|
| |
DANBURY, Conn., July 12, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today the award of two research grants by the Juvenile Diabetes Research Foundation (www.jdrf.org) to Stanford University and Oregon Health & Science University (OHSU) to evaluate the use of VIAject(R) (ultra-rapid-acting injectable human insu...
|
|
Biodel Announces Schedule for Presentations at the 37th Annual Meeting and Exposition of the Controlled Release Society
Jul 6, 2010
|
8.4 KB |
|
| |
DANBURY, Conn., July 6, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 37th Annual Meeting and Exposition of the Controlled Release Society in Portland, Oregon, U....
|
|
Biodel Abstracts to be Presented at 46th Annual Meeting of European Association for the Study of Diabetes
Jul 1, 2010
|
9.3 KB |
|
| |
DANBURY, Conn., July 1, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following abstracts describing results from studies of the company's product candidates have been accepted for presentation in September during the 46th annual meeting of the European Association for the Study of Diabetes in Stoc...
|
| Archived Releases |
|
Studies Demonstrate Potential Benefits of More-Rapid-Acting Injectable Insulins: Poster Presentations at Annual Meeting of the American Diabetes Association
Jun 26, 2010
|
13.8 KB |
|
| |
ORLANDO, Fla., June 26, 2010 /PRNewswire via COMTEX News Network/ -- Studies of a more-rapid-acting injectable human insulin formulation (VIAject(R)) in the treatment of type 1 and type 2 diabetes and of a novel insulin analog formulation (Vialog(TM)) in an animal model of diabetes were reported this week in three poster presentations at the 70th S...
|
|
Final Results of Phase 3 Study of VIAject(R) vs. Regular Human Insulin in Patients with Type 2 Diabetes Presented at American Diabetes Association Annual Meeting
Jun 25, 2010
|
12.6 KB |
|
| |
ORLANDO, Fla., June 25, 2010 /PRNewswire via COMTEX News Network/ -- The final results of a six-month, multi-center, open-label Phase 3 study of VIAject(R) (more-rapid-acting injectable human insulin) versus regular human insulin (RHI) in 471 patients with type 2 diabetes were presented today by Helena Rodbard, M.D., at the 70th Scientific Sessions...
|
|
Biodel Announces Schedule for Data Presentations at American Diabetes Association Annual Meeting
Jun 14, 2010
|
9.3 KB |
|
| |
DANBURY, Conn., June 14, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today that the following oral and poster presentations describing results from studies of the company's product candidates will be presented during the 70th Scientific Sessions of the American Diabetes Association this month in Orlando, Florid...
|
|
Biodel Appoints Donald Casey, Jr. to Board of Directors
Jun 3, 2010
|
11.1 KB |
|
| |
DANBURY, Conn., June 3, 2010 /PRNewswire via COMTEX News Network/ -- Biodel Inc. (Nasdaq: BIOD) announced today the appointment of Donald M. Casey, Jr. to its board of directors. Mr. Casey is former worldwide franchise chairman and company group chairman at Johnson & Johnson, where he worked for 25 years in a variety of senior marketing, business ...
|
|
Biodel Reports Second Quarter Fiscal Year 2010 Financial Results
May 6, 2010
|
20.3 KB |
|
| |
DANBURY, Conn., May 06, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the
second quarter ended March 31, 2010.
Second Quarter Financial Results
Biodel reported a net loss for the quarter ended March 31, 2010 of $10.4
million, or $0.44 per share, compared to a net loss of $11.6 million, or ...
|
|
Biodel to Report Second Quarter Fiscal Year 2010 Financial Results on May 6, 2010
May 3, 2010
|
9.1 KB |
|
| |
DANBURY, Conn., May 03, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) will issue its second quarter fiscal year
2010 financial results on May 6, 2010. Following the release of the
company's financial results, Biodel's senior management will host a
conference call to discuss the results and provide an update on the
...
|
|
Biodel Announces Senior Leadership Changes
Mar 30, 2010
|
13.5 KB |
|
| |
DANBURY, Conn., Mar 30, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) announced today the appointments of Dr. Errol
De Souza as president and chief executive officer and Dr. Charles
Sanders as board chairman, effective immediately. Dr. Solomon Steiner,
who co-founded Biodel in 2003, will become the company's chief
...
|
|
FDA Accepts VIAject(R) NDA for Review
Mar 1, 2010
|
10.0 KB |
|
| |
DANBURY, Conn., Mar 01, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) announced today that the U.S. Food and Drug
Administration has accepted for review the company's new drug
application (NDA) seeking approval to market VIAject(R) for the treatment
of diabetes. VIAject(R) is Biodel's proprietary formulation of recombin...
|
|
Biodel to Present Results from VIAject(R) Phase 3 Studies at Advanced Technologies and Treatments for Diabetes Conference in Basel
Feb 11, 2010
|
10.6 KB |
|
| |
DANBURY, Conn., Feb 11, 2010 (BUSINESS WIRE) -- Biodel, Inc. (Nasdaq: BIOD) announced today that its chief executive
officer, Dr. Sol Steiner, will present results from the company's two
Phase 3 studies with VIAject(R) ultra-rapid-acting recombinant human
insulin in a platform presentation at the 3rd International
Co...
|
|
Biodel Reports First Quarter Fiscal Year 2010 Financial Results
Feb 4, 2010
|
18.8 KB |
|
| |
DANBURY, Conn., Feb 04, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the
first fiscal quarter ended December 31, 2009.
First Quarter Financial Results
Biodel reported a net loss for the quarter ended December 31, 2009 of
$11.1 million, or $0.47 per share, compared to a net loss of $10.0
...
|
|
Biodel to Report First Quarter Fiscal Year 2010 Financial Results on February 4, 2010
Feb 1, 2010
|
8.9 KB |
|
| |
DANBURY, Conn., Feb 01, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) will issue its first quarter fiscal year 2010
financial results on February 4, 2010. Following the release of the
company's financial results, Biodel's senior management will host a
conference call to discuss the results and provide an update on the
...
|
|
Biodel Inc. to Present at 28th Annual JPMorgan Healthcare Conference on January 14th, 2010
Jan 6, 2010
|
7.7 KB |
|
| |
DANBURY, Conn., Jan 06, 2010 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) today announced that Dr. Solomon Steiner,
Chairman and CEO of Biodel, will present a corporate update at the 28th
Annual JPMorgan Healthcare Conference on Thursday, January 14, 2010 at
8:30 a.m. Pacific Time.
The JPMorgan Healthcare Conference will b...
|
|
Biodel Submits VIAject(R) New Drug Application to FDA for Treatment of Diabetes
Dec 30, 2009
|
12.0 KB |
|
| |
DANBURY, Conn., Dec 30, 2009 (BUSINESS WIRE) -- Biodel, Inc. (Nasdaq: BIOD) announced today that it has submitted a new
drug application (NDA) to the U.S. Food and Drug Administration for
clearance to market VIAject(R) as a treatment for diabetes. VIAject(R) is
Biodel's proprietary formulation of recombinant human insulin th...
|
|
Biodel Reports Fourth Quarter and Fiscal Year 2009 Financial Results
Dec 10, 2009
|
20.7 KB |
|
| |
DANBURY, Conn., Dec 10, 2009 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the
fourth quarter and fiscal year ended September 30, 2009.
Fourth Quarter and Fiscal Year 2009
Financial ResultsBiodel reported a net loss for the quarter ended September 30, 2009 of
$10.5 million, or $0.44 per ...
|
|
Biodel to Report Fourth Quarter and Fiscal Year 2009 Financial Results on December 10, 2009
Dec 7, 2009
|
8.1 KB |
|
| |
DANBURY, Conn., Dec 07, 2009 (BUSINESS WIRE) -- Biodel Inc. (Nasdaq: BIOD) will issue its fourth quarter and fiscal year
2009 financial results on December 10, 2009. Following the release of
the company's financial results, Biodel's senior management will host a
conference call to discuss the results and provide an update on...
|
|
|
